A seven-year controlled study shows that two Alzheimer's disease test drugs are not as effective as expected

Alzheimer's disease drugs have always been the "hardest bone" in the field, and the recent reports of the two drugs that have received much attention still seem to be unsatisfactory

Dominant hereditary Alzheimer’s disease is a rare form of Alzheimer’s disease (AD).

A team composed of Washington University School of Medicine and other institutions allowed 144 DIAD patients to receive "gantenerumab" or "solanezumab" or placebo treatment for a 7-year controlled study

Although no cognitive improvement or clinical benefit can be observed at this stage, many biological characteristics of AD patients in the "gantenerumab" group were significantly reduced, indicating that early treatment of DIAD still has potential benefits

The research team finally stated that the trial indicated the need for more optimized and more sensitive cognitive measurement of asymptomatic patients, and use of higher doses for a longer period of time to increase the effect of drugs and targets

These two drugs have always received considerable attention

As for another drug, "solanezumab", the US pharmaceutical giant Eli Lilly said in 2016 that it was very disappointed with the results of the drug's phase III clinical trial.

Editor-in-chief

This is disappointing news